AKR1B1

Across TCGA pan-cancer cohorts, AKR1B1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of AKR1B1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where AKR1B1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AKR1B1 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and PDAC are the cancer types where AKR1B1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AKR1B1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	−0.820	<.001	11	view →
COAD	Female	III,IV	−0.820	<.001	11	view →
PDAC	Male	II,III,IV	−0.381	<.001	8	view →
CCRCC	Female	IV	+1.096	<.001	7	view →
LSCC	All	All	−0.370	<.001	7	view →
LUAD	Male	All	−0.355	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

AKR1B1–HNSC

Open the HNSC breakdown →